Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

MMFS-202-302

"Active ingredient: L-Threonic acid Magnesium salt.~1 g (2 pills) by mouth once daily in the evening for 9 weeks~Drug: MMFS-302 Active ingredient: L-Threonic Acid Magnesium Salt~1 g (2 pills) by mouth once daily in the morning for 9 weeks"

DRUG

Placebo

Two tablets by mouth in the morning, and two tablets by mouth in the evening, daily for 9 weeks.

Trial Locations (1)

60611

Northwestern University Psychiatric Clinical Research Program, Chicago

All Listed Sponsors
collaborator

Neurocentria, Inc.

INDUSTRY

collaborator

Brain & Behavior Research Foundation

OTHER

lead

Northwestern University

OTHER